AU2012296977A1 - Novel compounds for the treatment of inflammatory bowel disease - Google Patents

Novel compounds for the treatment of inflammatory bowel disease Download PDF

Info

Publication number
AU2012296977A1
AU2012296977A1 AU2012296977A AU2012296977A AU2012296977A1 AU 2012296977 A1 AU2012296977 A1 AU 2012296977A1 AU 2012296977 A AU2012296977 A AU 2012296977A AU 2012296977 A AU2012296977 A AU 2012296977A AU 2012296977 A1 AU2012296977 A1 AU 2012296977A1
Authority
AU
Australia
Prior art keywords
mir
nucleic acid
sequence
acid molecule
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012296977A
Other languages
English (en)
Inventor
Christoph CICHON
Alexander Schmidt
Katharina VELTMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Westfaelische Wilhelms Universitaet Muenster
Original Assignee
Westfaelische Wilhelms Universitaet Muenster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westfaelische Wilhelms Universitaet Muenster filed Critical Westfaelische Wilhelms Universitaet Muenster
Publication of AU2012296977A1 publication Critical patent/AU2012296977A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012296977A 2011-08-12 2012-08-09 Novel compounds for the treatment of inflammatory bowel disease Abandoned AU2012296977A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11006650 2011-08-12
EP11006650.3 2011-08-12
EP11185604.3 2011-10-18
EP11185604 2011-10-18
PCT/EP2012/065568 WO2013023982A1 (en) 2011-08-12 2012-08-09 Novel compounds for the treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
AU2012296977A1 true AU2012296977A1 (en) 2014-01-23

Family

ID=46826440

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012296977A Abandoned AU2012296977A1 (en) 2011-08-12 2012-08-09 Novel compounds for the treatment of inflammatory bowel disease

Country Status (6)

Country Link
US (1) US20140199402A1 (https=)
EP (1) EP2742137A1 (https=)
JP (1) JP2014525749A (https=)
AU (1) AU2012296977A1 (https=)
CA (1) CA2840030A1 (https=)
WO (1) WO2013023982A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683263B2 (en) * 2013-05-20 2017-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection and treatment of irritable bowel syndrome
EP3060649A4 (en) 2013-10-23 2017-07-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
KR102733066B1 (ko) * 2015-06-26 2024-11-21 주식회사 파마리서치 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
WO2016208880A1 (ko) * 2015-06-26 2016-12-29 주식회사 파마리서치프로덕트 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
EP3969019A4 (en) * 2019-05-14 2023-06-07 Hadasit Medical Research Services and Development Ltd. MILK-DERIVED EXTRACELLULAR VESICLES FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
ES2535419T3 (es) * 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
WO2009120877A2 (en) * 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
WO2010034479A1 (en) 2008-09-23 2010-04-01 Eth Zurich Protective e. coli strains for reducing the salmonella typhimurium pathogen load in the intestines

Also Published As

Publication number Publication date
EP2742137A1 (en) 2014-06-18
US20140199402A1 (en) 2014-07-17
CA2840030A1 (en) 2013-02-21
WO2013023982A1 (en) 2013-02-21
JP2014525749A (ja) 2014-10-02

Similar Documents

Publication Publication Date Title
US11266698B2 (en) Bacterium for use as a probiotic for nutritional and medical applications
EP2344626B1 (en) Reduced colonization of microbes at the mucosa
Guzman et al. Diet, microbiome, and the intestinal epithelium: an essential triumvirate?
Mizuno et al. Exopolysaccharides from Streptococcus thermophilus ST538 modulate the antiviral innate immune response in porcine intestinal epitheliocytes
CA2694354C (en) Lactic acid bacteria-derived double-stranded rna
US20140199402A1 (en) Novel compounds for the treatment of inflammatory bowel disease
Taibi et al. Time‐and strain‐specific downregulation of intestinal EPAS1 via miR‐148a by Bifidobacterium bifidum
WO2010067882A1 (ja) 癌及び喘息治療のための医薬組成物
Bailey et al. Identification and characterisation of an iron-responsive candidate probiotic
KR101611833B1 (ko) 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 락토바실루스 아시도필루스 cbt la1 균주 및 이를 포함하는 조성물
KR20210039495A (ko) 피드백이 가능한 합성 유전자, 표적 시드 매치 카세트, 및 그 용도
Ogita et al. Suppression of Th17 response by Streptococcus thermophilus ST28 through induction of IFN-γ
CN104099279A (zh) 一种缓解畜禽应激的复合微生态制剂及应用
CN112972702A (zh) 用于治疗耐药菌感染的外泌体制剂
Khokhlova et al. Heterologous expression of secreted biologically active human interleukin-10 in Bifidobacterium breve
JP2023033337A (ja) 糖吸収促進用組成物
CN110049770A (zh) 肌肉分化诱导剂
JP2023546022A (ja) 腸内での繊維合成酵素の発現のための操作されたプロバイオティクス
JP5660537B2 (ja) 乳酸菌により二本鎖ｒｎａを生成するキット及びその利用
Albarracin et al. Exopolysaccharides From Streptococcus thermophilus ST538
Ghatani et al. Bifidobacterial Genome Editing for Potential Probiotic Development
WO2026090394A1 (en) Engineered n-lactoyl-phenylalanine producing bacteria to protect against obesity
LeBegue The Pharmabiotic for Phenylketonuria: Development of a Novel Therapeutic
WO2019036859A1 (zh) 分泌glp-1及其衍生物的蛋白表达系统及其制备方法和用途
HK40074611A (en) Gaba-producing culturable bacteria and use for improving health

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted